1319 GMT - U.K. pharmaceutical stocks could perform better than their European counterparts in the short and medium term if the U.K. gets a chance to bargain for lighter tariffs, XTB's Kathleen Brooks says in a note. The U.K. is better positioned to negotiate favorable terms with the U.S. as it has a small trade deficit with the U.S., especially compared to Germany, she says. If it looks likely that the U.K. could negotiate a lower tariff rate with the U.S. compared to the EU, then pharma giant GSK could be one notable candidate that could outperform, she says. Other U.K. pharmaceutical stocks like Smith and Nephew, and AstraZeneca are likely to benefit, she says. (miriam.mukuru@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 09:19 ET (13:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。